Prolonged release oxycodone–naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension
Claudia Trenkwalder(Paracelsus Elena Klinik Kassel), Ralf Kohnen(Friedrich-Alexander-Universität Erlangen-Nürnberg), A. Oksche(Justus-Liebig-Universität Gießen), Juliane Winkelmann(Helmholtz Zentrum München), Diego Garcı́a-Borreguero(Sleep Research Society), Michael Hopp(Johannes Gutenberg University Mainz), K. Reimer(Witten/Herdecke University), Ludger Grote(Sahlgrenska University Hospital), Heike Beneš(Siesta Group (Austria)), Björn Bosse(Mundipharma (Germany)), Birgit Högl(Innsbruck Medical University), Richard P. Allen(Johns Hopkins University)
Cited by 227
Related Papers
European guideline for the diagnosis and treatment of insomnia
|Journal of Sleep Research|2017|2k
Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study
|Brain|2019|1.1k
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
|Nature Genetics|2012|1k
Effect of Nasal Continuous Positive Airway Pressure Treatment on Blood Pressure in Patients With Obstructive Sleep Apnea
|Circulation|2003|929
The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023
|Journal of Sleep Research|2023|703